MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
DiaMedica Therapeutics EPS Ratio 2011-2026 | DMAC
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio DiaMedica Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.6 | -0.52 | -0.65 | -0.78 | -0.89 | -0.74 | -0.72 | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.52 | -0.89 | -0.7 |
Quarterly EPS Ratio DiaMedica Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.17 | -0.18 | -0.18 | - | -0.15 | -0.13 | -0.14 | - | -0.12 | -0.16 | -0.2 | - | -0.12 | -0.13 | -0.13 | - | -0.18 | -0.17 | -0.19 | - | -0.19 | -0.17 | -0.19 | - | -0.2 | -0.21 | -0.27 | - | -0.18 | -0.22 | -0.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -0.1 | -0.27 | -0.17 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M |  Germany |
 |
Xeris Pharmaceuticals
XERS
|
-0.37 | $ 6.03 | -1.55 % | $ 885 M |  USA |
 |
I-Mab
IMAB
|
-7.66 | - | - | $ 866 M |  China |
 |
UroGen Pharma Ltd.
URGN
|
-3.19 | $ 19.2 | -11.52 % | $ 554 M |  Israel |
 |
uniQure N.V.
QURE
|
-3.46 | $ 10.89 | -30.36 % | $ 530 M |  Niderland |
 |
GT Biopharma
GTBP
|
-6.68 | $ 0.47 | -2.41 % | $ 892 K | USA |
 |
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M |  France |
 |
AbCellera Biologics
ABCL
|
-0.49 | $ 3.74 | 3.6 % | $ 1.12 B |  Canada |
 |
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
-6.62 | - | - | $ 86.2 M | USA |
 |
ARCA biopharma
ABIO
|
-3.87 | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
-1.66 | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-1.73 | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
-204 | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
-0.79 | - | 4.01 % | $ 150 M | Canada |
 |
CureVac N.V.
CVAC
|
-2.21 | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-0.07 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-13.7 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-2.38 | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
-0.69 | $ 3.36 | 0.86 % | $ 1.2 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.46 | - | - | $ 7.46 M | Israel |
 |
Akero Therapeutics
AKRO
|
-3.75 | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
-7.12 | $ 29.16 | -3.54 % | $ 1.69 B | USA |
 |
Advaxis
ADXS
|
-7.99 | - | -9.65 % | $ 45.9 M | USA |
 |
Akouos
AKUS
|
-2.52 | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-1.77 | - | -0.23 % | $ 916 M | USA |
 |
Alector
ALEC
|
-1.39 | $ 2.19 | -9.77 % | $ 226 M | USA |
 |
Entera Bio Ltd.
ENTX
|
0.54 | $ 1.38 | -0.72 % | $ 63.3 M | Israel |
 |
Allena Pharmaceuticals
ALNA
|
-0.72 | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
-3.51 | - | 10.36 % | $ 9.8 M | USA |
 |
Altimmune
ALT
|
-1.34 | $ 4.21 | -2.32 % | $ 299 M | USA |
 |
AlloVir
ALVR
|
-11.7 | - | 4.14 % | $ 49.1 M | USA |
 |
Evogene Ltd.
EVGN
|
-0.83 | $ 0.84 | -4.24 % | $ 27.9 M | Israel |
 |
Ampio Pharmaceuticals
AMPE
|
-10.7 | - | -11.43 % | $ 502 K | USA |
 |
Amarin Corporation plc
AMRN
|
-0.09 | $ 13.98 | 1.27 % | $ 5.7 B |  Irlanda |
 |
AbbVie
ABBV
|
1.02 | $ 233.57 | 0.64 % | $ 413 B | USA |
 |
Blueprint Medicines Corporation
BPMC
|
-1.07 | - | - | $ 8.14 B | USA |
 |
Applied Molecular Transport
AMTI
|
-3.25 | - | - | $ 10.1 M | USA |
 |
AIM ImmunoTech
AIM
|
-0.4 | $ 0.8 | -11.6 % | $ 38.5 M | USA |
 |
Aptorum Group Limited
APM
|
-0.78 | $ 0.83 | 5.37 % | $ 4.53 M | China |
 |
Apellis Pharmaceuticals
APLS
|
0.18 | $ 20.67 | -1.38 % | $ 2.61 B | USA |